MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

BKT

12.495

-0.12%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

BKT

12.495

-0.12%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

BKT

12.495

-0.12%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

BKT

12.495

-0.12%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

BKT

12.495

-0.12%↓

Search

Sartorius Stedim Biotech.

Geschlossen

BrancheFinanzen

168.85 -1.14

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

167.75

Max

171.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

-47M

69M

Verkäufe

400K

745M

KGV

Branchendurchschnitt

76.147

25.916

EPS

1.18

Dividendenrendite

0.39

Gewinnspanne

9.195

Angestellte

10,030

EBITDA

124M

256M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+33.63% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.39%

3.70%

Nächstes Ergebnis

16. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

92M

20B

Vorheriger Eröffnungskurs

169.99

Vorheriger Schlusskurs

168.85

Nachrichtenstimmung

By Acuity

20%

80%

29 / 536 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Sartorius Stedim Biotech. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 21:42 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. Aug. 2025, 21:21 UTC

Ergebnisse
Wichtige Markttreiber

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. Aug. 2025, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. Aug. 2025, 19:15 UTC

Wichtige Markttreiber

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. Aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. Aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. Aug. 2025, 21:30 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 21:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. Aug. 2025, 21:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. Aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss $938M >RIG

4. Aug. 2025, 20:25 UTC

Ergebnisse

Transocean 2Q Loss/Shr $1.06 >RIG

4. Aug. 2025, 20:18 UTC

Ergebnisse

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. Aug. 2025, 20:15 UTC

Ergebnisse

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. Aug. 2025, 20:14 UTC

Ergebnisse

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. Aug. 2025, 20:13 UTC

Ergebnisse

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. Aug. 2025, 20:09 UTC

Ergebnisse

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. Aug. 2025, 20:06 UTC

Ergebnisse

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. Aug. 2025, 20:01 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. Aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. Aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. Aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. Aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer-Vergleich

Kursveränderung

Sartorius Stedim Biotech. Prognose

Kursziel

By TipRanks

33.63% Vorteil

12-Monats-Prognose

Durchschnitt 229.38 EUR  33.63%

Hoch 245 EUR

Tief 210 EUR

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius Stedim Biotech. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

6

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

202.7 / 211.7Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

29 / 536 Ranking in Finanzen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.